Beyond antibodies: New affinity reagents to unlock the proteome

Proteomics

Volumn 14, Issue 6, 2014, Pages 638-644

  Lollo, Bridget ^a   Steele, Fintan ^a   Gold, Larry ^a  

^a SomaLogic Inc   (United States)

Author keywords

Aptamer; Biomarker; Protein arrays; SOMAmer; SOMAscan

Indexed keywords

ANTIBODY; APTAMER; BIOLOGICAL MARKER; PROTEOME; REAGENT;

NOTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEOMICS; VALIDATION STUDY;

APTAMER; BIOMARKER; PROTEIN ARRAYS; SOMAMER; SOMASCAN;

ANIMALS; ANTIBODIES; APTAMERS, NUCLEOTIDE; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS;

EID: 84895743899     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300187     Document Type: Note

References (55)

1. Yalow, R. S., Berson, S. A., Assay of plasma insulin in human subjects by immunological methods. Nature 1959, 184, 1648-1649.
2. Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
3. Bradbury, A. R., Sidhu, S., Dubel, S., McCafferty, J., Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 2011, 29, 245-254.
4. McCafferty, J., Griffiths, A. D., Winter, G., Chiswell, D. J., Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348, 552-554.
5. Barbas, C. F., 3rd, Kang, A. S., Lerner, R. A., Benkovic, S. J., Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7978-7982.
6. Barbas, C. F., 3rd, Synthetic human antibodies. Nat. Med. 1995, 1, 837-839.
7. Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
8. Ellington, A. D., Szostak, J. W., In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822.
9. Gold, L., Polisky, B., Uhlenbeck, O., Yarus, M., Diversity of oligonucleotide functions. Annu. Rev. Biochem. 1995, 64, 763-797.
10. Gold, L., Ayers, D., Bertino, J., Bock, C. et al., Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS One 2010, 5, e15004.
11. Missailidis, S., Hardy, A., Aptamers as inhibitors of target proteins. Expert Opin. Ther. Pat. 2009, 19, 1073-1082.
12. Jayasena, S. D., Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999, 45, 1628-1650.
13. Rimmele, M., Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003, 4, 963-971.
14. McKeague, M., Derosa, M. C., Challenges and opportunities for small molecule aptamer development. J Nucleic Acids 2012, 2012, 748913.
15. Yoshida, Y., Waga, I., Horii, K., Quantitative and sensitive protein detection strategies based on aptamers. Proteomics Clin. Appl. 2012, 6, 574-580.
16. Bunka, D. H., Stockley, P. G., Aptamers come of age-at last. Nat. Rev. Microbiol. 2006, 4, 588-596.
17. Stoltenburg, R., Reinemann, C., Strehlitz, B., SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24, 381-403.
18. Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M. et al., Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994, 13, 3245-3260.
19. Foote, J., Eisen, H. N., Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1254-1256.
20. Ahmad, K. M., Oh, S. S., Kim, S., McClellen, F. M. et al., Probing the limits of aptamer affinity with a microfluidic SELEX platform. PloS One 2011, 6, e27051.
21. Latham, J. A., Johnson, R., Toole, J. J., The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. Nucleic Acids Res. 1994, 22, 2817-2822.
22. Vaught, J. D., Bock, C., Carter, J., Fitzwater, T. et al., Expanding the chemistry of DNA for in vitro selection. J Am. Chem. Soc. 2010, 132, 4141-4151.
23. Jenison, R. D., Gill, S. C., Pardi, A., Polisky, B., High-resolution molecular discrimination by RNA. Science 1994, 263, 1425-1429.
24. Kimoto, M., Shirouzu, M., Mizutani, S., Koide, H. et al., Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. Eur. J. Biochem./FEBS 2002, 962, 407-796.
25. Jellinek, D., Lynott, C. K., Rifkin, D. B., Janjic, N., High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 11227-11231.
26. Hopfield, J. J., Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 4135-4139.
27. Ninio, J., Kinetic amplification of enzyme discrimination. Biochimie 1975, 57, 587-595.
28. Gold, L., Janjic, N., Jarvis, T., Schneider, D. et al., Aptamers and the RNA world, past and present. Cold Spring Harb. Perspect. Biol. 2012, 4.
29. Davies, D. R., Gelinas, A. D., Zhang, C., Rohloff, J. C. et al., Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 19971-19976.
30. Hoogenboom, H. R., Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 2005, 23, 1105-1116.
31. Burke, D. H., Scates, L., Andrews, K., Gold, L., Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J. Mol. Biol. 1996, 264, 650-666.
32. Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K. et al., DNA aptamers block l-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J. Clin. Invest. 1996, 98, 2688-2692.
33. Jellinek, D., Green, L. S., Bell, C., Janjic, N., Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994, 33, 10450-10456.
34. Ringquist, S., Parma, D., Anti-l-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: binding affinity and specificity of univalent and bivalent ligands. Cytometry 1998, 33, 394-405.
35. Gupta, S., Thirstrup, D., Jarvis, T. C., Schneider, D. J. et al., Rapid histochemistry using slow off-rate modified aptamers with anionic competition. Appl. Immunohistochem. Mol. Morphol. 2011, 91, 273-278.
36. Mehan, M. R., Ayers, D., Thirstrup, D., Xiong, W. et al., Protein signature of lung cancer tissues. PloS One 2012, 7, e35157.
37. Ramaraj, T., Angel, T., Dratz, E. A., Jesaitis, A. J., Mumey, B., Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. Biochim. Biophys. Acta 2012, 1824, 520-532.
38. Marx, V., Finding the right antibody for the job. Nat. Methods 2013, 10, 703-707.
39. Walsh, G., Jefferis, R., Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 2006, 24, 1241-1252.
40. Haab, B. B., Methods and applications of antibody microarrays in cancer research. Proteomics 2003, 3, 2116-2122.
41. Ellington, A. A., Kullo, I. J., Bailey, K. R., Klee, G. G., Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 2010, 56, 186-193.
42. Brody, E., Gold, L., Mehan, M., Ostroff, R. et al., Life's simple measures: unlocking the proteome. J. Mol. Biol. 2012, 422, 595-606.
43. Baird, G. S., Nelson, S. K., Keeney, T. R., Stewart, A. et al., Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am. J. Pathol. 2012, 180, 446-456.
44. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., Wang, P., The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2008, 2, 1386-1402.
45. Ostroff, R. M., Bigbee, W. L., Franklin, W., Gold, L. et al., Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PloS One 2010, 5, e15003.
46. Ostroff, R. M., Mehan, M. R., Stewart, A., Ayers, D. et al., Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PloS One 2012, 7, e46091.
47. Pavlou, M. P., Diamandis, E. P., Blasutig, I. M., The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 2013, 59, 147-157.
48. Ostroff, R., Foreman, T., Keeney, T. R., Stratford, S. et al., The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. J. Proteomics 2010, 73, 649-666.
49. Frystyk, J., Freda, P., Clemmons, D. R., The current status of IGF-I assays-a 2009 update. Growth Horm. IGF Res. 2010, 20, 8-18.
50. Mire-Sluis, A. R., Gaines-Das, R., Thorpe, R., Immunoassays for detecting cytokines: what are they really measuring? J. Immunol. Methods 1995, 186, 157-160.
51. Park, N. J., Wang, X., Diaz, A., Goos-Root, D. M. et al., Measurement of cetuximab and panitumumab-unbound serum egfr extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents. PloS One 2013, 8, e71703.
52. Kraemer, S., Vaught, J. D., Bock, C., Gold, L. et al., From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PloS one 2011, 6, e26332.
53. Park, N.-J., Wang, W., Root, D., Diaz, A., Sun, W., Morrone, R. J., Waldman, F., Strom, C. M., Development of an assay based on SOMAmer affinity reagents that detects drug-unbound serum EGFR in the presence of cetuximab and panitumumab. J. Clin. Oncol. 2012, 30, abstract 2587.
54. Ochsner, U., Katilius, E., Janjic, N., Detection of Clostridium difficile toxins A, B and Binary Toxin with slow off-rate modified aptamers. Diagn. Microbiol. Infect. Dis. 2013, 76, 278-285.
55. Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J. et al., Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153, 828-839.